Paper39218342
Nanomedicine: A great boon for cardiac regenerative medicine.
Choudhury P and 3 others. Eur J Pharmacol, 2024. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Nanomedicine: A great boon for cardiac regenerative medicine. Papers, record 39218342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39218342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Regenerative Medicine | Major topic |
| Nanomedicine | Major topic |
| Humans | |
| Animals | |
| Nanoparticles | |
| Cardiovascular Diseases | |
| Drug Delivery Systems | |
| Regeneration | |
| Heart |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42726851 | AT1R-mediated NIR-II/PA imaging-guided iCM exosome therapy for myocardial ischemia revascularization. | Sci Adv | 2026 | https://conductscience.org/library/papers/42726851 | PubMed |
| 42579251 | Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies. | Discov Nano | 2026 | https://conductscience.org/library/papers/42579251 | PubMed |
| 42243568 | Injectable pre-vascularized alginate-collagen hydrogel with sustained delivery of miR-133a-loaded lipid nanoparticles for myocardial repair. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42243568 | PubMed |
| 42181879 | A catalase nanocapsule inhibits VSMCs proliferation and migration through PTEN/NLRP3 pathway. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42181879 | PubMed |
| 42016346 | Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42016346 | PubMed |
| 41971085 | Platelet mitochondria dysfunction in diabetes mellitus: mechanisms and therapeutic implications. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41971085 | PubMed |
| 41458538 | Editorial: The complex phenotype of diabetic cardiomyopathy: clinical indicators and novel treatment targets, volume II. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41458538 | PubMed |
| 41210329 | Nanoparticle-based drug delivery systems targeting inflammatory immune mechanisms in acute myocardial infarction: current advances and perspectives. | Front Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41210329 | PubMed |
| 41158128 | Diabetic cardiomyopathy and COVID-19: intersecting pathways and amplified cardiovascular risk. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41158128 | PubMed |
| 40785184 | Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis. | Mol Ther | 2025 | https://conductscience.org/library/papers/40785184 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39218342
GET https://conductscience.org/api/papers/v1/39218342/authors